LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. Phase 1b/2 study of combination 177Lu girentuximab plus ...
Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.
Naomi Haas, MD, from the Hospital at the University of Pennsylvania, explains that most trials regarding neoadjuvant therapy ...
Investigators sought to determine whether a ctDNA-guided adjuvant atezolizumab dosing strategy was more cost-effective than a standard stage-based strategy for patients with MIBC.
Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the ...
After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...
After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer (NSCLC). Using ...
Vaccines save lives, as proven during the recent pandemic, but one component of most vaccines—including the Novavax COVID-19 vaccine—goes unheralded: a molecule or other compound that primes the ...
Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline BRCA1/2-Mutated Breast Cancers in the High-Risk, Early-Stage Setting Targeted tyrosine kinase inhibitors (TKIs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results